223 related articles for article (PubMed ID: 37993001)
21. Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity.
Zheng Y; Yao Y; Ge T; Ge S; Jia R; Song X; Zhuang A
J Exp Clin Cancer Res; 2023 Nov; 42(1):291. PubMed ID: 37924140
[TBL] [Abstract][Full Text] [Related]
22. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy.
Lim AR; Rathmell WK; Rathmell JC
Elife; 2020 May; 9():. PubMed ID: 32367803
[TBL] [Abstract][Full Text] [Related]
23. Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
Giordano Attianese GMP; Ash S; Irving M
Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063
[TBL] [Abstract][Full Text] [Related]
24. Tumor glucose metabolism and the T cell glycocalyx: implication for T cell function.
Schuurmans F; Wagemans KE; Adema GJ; Cornelissen LAM
Front Immunol; 2024; 15():1409238. PubMed ID: 38881904
[TBL] [Abstract][Full Text] [Related]
25. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
Bader JE; Voss K; Rathmell JC
Mol Cell; 2020 Jun; 78(6):1019-1033. PubMed ID: 32559423
[TBL] [Abstract][Full Text] [Related]
26. Obstacles for T-lymphocytes in the tumour microenvironment: Therapeutic challenges, advances and opportunities beyond immune checkpoint.
Verma NK; Wong BHS; Poh ZS; Udayakumar A; Verma R; Goh RKJ; Duggan SP; Shelat VG; Chandy KG; Grigoropoulos NF
EBioMedicine; 2022 Sep; 83():104216. PubMed ID: 35986950
[TBL] [Abstract][Full Text] [Related]
27. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer.
Zhao L; Liu Y; Zhang S; Wei L; Cheng H; Wang J; Wang J
Cell Death Dis; 2022 Apr; 13(4):378. PubMed ID: 35444235
[TBL] [Abstract][Full Text] [Related]
28. Ionic Regulation of T-Cell Function and Anti-Tumour Immunity.
Ginefra P; Carrasco Hope H; Spagna M; Zecchillo A; Vannini N
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948472
[TBL] [Abstract][Full Text] [Related]
29. Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment.
Ma G; Zhang Z; Li P; Zhang Z; Zeng M; Liang Z; Li D; Wang L; Chen Y; Liang Y; Niu H
Cell Commun Signal; 2022 Jul; 20(1):114. PubMed ID: 35897036
[TBL] [Abstract][Full Text] [Related]
30. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.
Yin Z; Bai L; Li W; Zeng T; Tian H; Cui J
J Exp Clin Cancer Res; 2019 Sep; 38(1):403. PubMed ID: 31519198
[TBL] [Abstract][Full Text] [Related]
31. Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Vigano S; Alatzoglou D; Irving M; Ménétrier-Caux C; Caux C; Romero P; Coukos G
Front Immunol; 2019; 10():925. PubMed ID: 31244820
[TBL] [Abstract][Full Text] [Related]
32. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
33. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
34. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
Bahrambeigi S; Shafiei-Irannejad V
Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
[TBL] [Abstract][Full Text] [Related]
35. Helper innate lymphoid cells as cell therapy for cancer.
Magnusson FC; Bahhar I
Immunology; 2023 Apr; 168(4):569-579. PubMed ID: 36288454
[TBL] [Abstract][Full Text] [Related]
36. [Latest Findings on the Function of Immune Metabolism in Tumor Immunity].
Yang Y; Fan D; Zheng BH; Zhou ST
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):497-504. PubMed ID: 37248574
[TBL] [Abstract][Full Text] [Related]
37. The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy.
Li D; Cao D; Sun Y; Cui Y; Zhang Y; Jiang J; Cao X
Front Immunol; 2024; 15():1331641. PubMed ID: 38348027
[TBL] [Abstract][Full Text] [Related]
38. Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations.
Colton M; Cheadle EJ; Honeychurch J; Illidge TM
Radiat Oncol; 2020 Nov; 15(1):254. PubMed ID: 33148287
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
[TBL] [Abstract][Full Text] [Related]
40. Advances in macrophage and T cell metabolic reprogramming and immunotherapy in the tumor microenvironment.
Cheng H; Zheng Y
PeerJ; 2024; 12():e16825. PubMed ID: 38239299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
